The business conference "CHUGAI INNOVATION DAY 2025" hosted by Chugai Pharmaceutical was held at Marunouchi Building Hall & Conference Square (Marunouchi, Tokyo) over two days on November 27nd and 28th(Thu-Fri), 2025.

This year's theme, marking the memorable milestone of the Chugai's 100th anniversary, was "The Intersection of Innovation Creating the Future of Healthcare."

On the first day, a keynote speech was delivered by President & CEO Dr. Osamu Okuda, and throughout both days, the importance of "co-creation" and the direction of open innovation that Chugai Pharmaceutical aims for were discussed with speakers from both inside and outside the company. This event was planned as an opportunity to create connections with external partners, focusing on innovation creation through co-creation, looking ahead to the future of the healthcare industry through science and technology, and aimed to promote dialogue and collaboration across industry boundaries.

The event was held in a hybrid style with both in-person and online participation, attracting many participants from a wide range of sectors including pharmaceutical, life sciences, technology companies, academia, and students.

This report mainly covers the poster sessions that were held only on-site.
For information about the lectures and discussions, please refer to the reports below.

CHUGAI INNOVATION DAY 2025 Event Report (DAY1)(Japanese only)
https://prtimes.jp/main/html/rd/p/000000008.000089750.html

CHUGAI INNOVATION DAY 2025 Event Report (DAY2)(Japanese only)
https://prtimes.jp/main/html/rd/p/000000009.000089750.html

Poster presentations were held introducing initiatives focused on Chugai Pharmaceutical's co-creative innovation. The presentations, centered on the event concept of "co-creation," introduced initiatives by company employees aiming for patient contribution across 15 themes, ranging from drug discovery research to clinical development, production, and post-marketing, including examples of collaboration with external partners and innovation creation through cross-departmental projects.

Active exchanges with participants helped create opportunities to activate collaboration in the healthcare industry.

Participants commented that they "were able to hear from professionals both inside and outside Chugai Pharmaceutical" and that "the content was substantial." We will continue to contribute to the creation of innovation and the development of the industry through such opportunities.

・Reliability Assurance Unit

- Challenges in Digital Utilization in Sales Information Provision Activity Supervision Systems

・Digital Transformation Unit

- Analytical Co-creation and Autonomy — Fostering a Data-Driven Culture —

- Chugai Pharmaceutical's Initiatives Toward Quantum Computer Utilization

・PHC Solutions Unit

- The Present and Future of Cancer Treatment Opened by Genome Profiling

- Personalized Healthcare (PHC) Solutions ~ Providing Optimal Value Tailored to Each Individual Patient

・Project Lifecycle Management Unit

- Regulatory DX Created by Everyone, Used by Everyone

・Translational Research Division

- Feasibility of Stress and QOL Assessment Using Wearable Device Data: Correlation Analysis Between Heart Rate Variability and Patient-Reported Outcomes

- Scientifically Studying the Ultimate Biosensor "Nose" — Does Body Odor Change with Fatty Liver? —

- Spatial Transcriptome Analysis Using Diverse Liver Injury Samples

~ Challenges Toward New Discoveries for Adverse Event Treatment Strategies Based on Molecular Mechanisms to Reduce irAE in Cancer Immunotherapy ~

・Research Division

- Search for Celiac Disease Diagnostic Markers Using UK Biobank Plasma Proteomics Data

・Clinical Development Division

- Innovation in Clinical Development Data Management: Initiatives for Electronic Medical Record-EDC Integration and Data Utilization Improvement

・Pharmaceutical Technology Division

- Nemolizumab: Global Launch Through Chugai's First Third-Party Joint Development

・Pharmacovigilance Division

- Genetic drivers of severe skin toxicity with immune checkpoint inhibitors (ICIs) in Asian patients

・Sales Division

- Not Just "Treatment," But Beyond — Forms of Information Support That Chugai Pharmaceutical Realizes to Accompany Patients' Lives

・Corporate

- Contribution to Global Health Through Partnering of AID351

- Chugai Pharmaceutical 100th Anniversary Commemorative Panel

*Reproduced from Chugai Pharmaceutical’s official Note page（https://note.chugai-pharm.co.jp/）Article details and employee positions are current as of December 2025